KalVista Pharmaceuticals

creating a new generation of small molecule protease inhibitors for HAE and DME

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)